Actively Recruiting
Multidimensional Apathy in Psychiatric Pathologies.
Led by University Hospital, Strasbourg, France · Updated on 2025-08-03
144
Participants Needed
1
Research Sites
268 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Apathy is defined by quantitative decrease in goal-directed activity in comparison to the person's previous level of functioning. Apathy is a transnosographic symptom, prevalent in many neurological and psychiatric pathologies (specifically in schizophrenia and depression), and almost half of patients suffer from it. It is an important source of burden, affecting both personal and occupational life. Despite its high prevalence and negative consequences, no pharmacological or non-pharmacological treatments exist, the underlying mechanisms of apathy being poorly understood. The main aim of the present study is to advance in our knowledge of cognitive and neural mechanisms of apathy by using a multidimensional model of apathy, distinguishing three forms: executive, emotional and auto-activation/initiative. the investigators hypothesize, independently of the pathology (schizophrenia and depression), the existence of different cognitive deficits underlying each of the 3 subforms of apathy. Indeed, according to the predictions of Levy and Dubois' model (2006), executive disorders underlie the cognitive form of apathy. It may be related to lesions of the dorsolateral prefrontal cortex and the cognitive territory of the basal ganglia. Emotional apathy could be due to motivational disorder. Dysfunctions or lesions in the orbital and medial prefrontal cortex and limbic territories of the basal ganglia may underlie this. Finally, the initiative form, may be a mixed form, with both motivational and executive difficulties. Lesions or dysfunctions may affect both the cognitive and limbic territories of the basal ganglia or the anterior cingulate cortex.
CONDITIONS
Official Title
Multidimensional Apathy in Psychiatric Pathologies.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 60 years
- Men or women volunteers, hospitalized or not
- Affiliated with a health insurance
- Signed informed consent
- For schizophrenic patients: meet DSM-V TR criteria for schizophrenia
- For depressive patients: meet DSM-V TR criteria for depression
You will not qualify if you...
- Major or unstable somatic disorder
- Medical history affecting brain anatomy or causing abnormalities (e.g., neonatal distress, neurosurgery, neurological disorders, stroke)
- Disorders related to psycho-active substance use (as per DSM-IV)
- Sensory disabling impairments, especially visual acuity less than 8
- General anesthesia within 3 months before the study
- Pregnancy
- Emergency situations
- Persons deprived of liberty
- Participation in another protocol exclusion period
- For controls: use of psychotropic substances within 3 weeks before the study
- For patients: use of benzodiazepines
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Service de Psychiatrie, Hôpital Civil, Hôpitaux Universitaires de Strasbourg
Strasbourg, France, 67091
Actively Recruiting
Research Team
F
Fabrice Berna, MD
CONTACT
A
Anne Bonnefond, PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
FACTORIAL
Primary Purpose
OTHER
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here